Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 14;64(1):216-232.
doi: 10.1021/acs.jmedchem.0c01530. Epub 2020 Dec 31.

Peptide-Drug Conjugates with Different Linkers for Cancer Therapy

Mona Alas  1 , Azam Saghaeidehkordi  1 , Kamaljit Kaur  1
Affiliations
Review

Peptide-Drug Conjugates with Different Linkers for Cancer Therapy

Mona Alas et al. J Med Chem. .

Abstract

Drug conjugates are chemotherapeutic or cytotoxic agents covalently linked to targeting ligands such as an antibody or a peptide via a linker. While antibody-drug conjugates (ADCs) are now clinically established for cancer therapy, peptide-drug conjugates (PDCs) are gaining recognition as a new modality for targeted drug delivery with improved efficacy and reduced side effects for cancer treatment. The linker in a drug conjugate plays a key role in the circulation time of the conjugate and release of the drug for full activity at the target site. Herein, we highlight the main linker chemistries utilized in the design of PDCs and discuss representative examples of PDCs with different linker chemistries with the related outcome in cell and animal studies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1.
Figure 1.
Schematic of a PDC. The chemical structures of different linker chemistries are shown with the plausible method of release of the drug from PDC after cellular uptake or under in vivo conditions.
Figure 2.
Figure 2.
PDCs with an ester and/or an amide as linkers. The peptide is shown in red, the linker in blue, and the drug in black. D-amino acids are shown in lower case.
Figure 3.
Figure 3.
PDCs with a carbamate linker. D-amino acids are shown in lower case.
Figure 4.
Figure 4.
PDCs with a dipeptide or tripeptide linker.
Figure 5.
Figure 5.
PDCs with an amide and a succinimidyl thioether as linkers.
Figure 6.
Figure 6.
Peptide-drug conjugate with the ring closed succinimidyl thioether and ring-open stable thioether.
Figure 7.
Figure 7.
PDCs with an ester and a triazole as linkers.
Figure 8.
Figure 8.
Drug conjugates with a hydrazone bond as a linker.
Figure 9.
Figure 9.
PDCs with a disulfide as a linker.
Figure 10.
Figure 10.
PDCs with an oxime as a linker.
Figure 11.
Figure 11.
PDC with triazole linkers.
Figure 12.
Figure 12.
Structures of some approved ADCs with different linker chemistries. The antibody is shown in green, the linker in blue, and the drug in black.
See this image and copyright information in PMC

References

    1. Gotwals P; Cameron S; Cipolletta D; Cremasco V; Crystal A; Hewes B; Mueller B; Quaratino S; Sabatos-Peyton C; Petruzzelli L; Engelman JA; Dranoff G, Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer 2017, 17 (5), 286–301. - PubMed
    1. Mitra AK; Agrahari V; Mandal A; Cholkar K; Natarajan C; Shah S; Joseph M; Trinh HM; Vaishya R; Yang X; Hao Y; Khurana V; Pal D, Novel delivery approaches for cancer therapeutics. J Control Release 2015, 219, 248–268. - PMC - PubMed
    1. Chau CH; Steeg PS; Figg WD, Antibody-drug conjugates for cancer. Lancet 2019, 394 (10200), 793–804. - PubMed
    1. He R; Finan B; Mayer JP; DiMarchi RD, Peptide conjugates with small molecules designed to enhance efficacy and safety. Molecules 2019, 24 (10), 1855. - PMC - PubMed
    1. Thomas A; Teicher BA; Hassan R, Antibody-drug conjugates for cancer therapy. Lancet Oncol 2016, 17 (6), e254–e262. - PMC - PubMed

Publication types